Gastric cancer (GC) is one of the most malignant human cancers with increasing incidence worldwide, ranking among the top five malignant tumors worldwide in terms of incidence and mortality. The clinical efficacy of conventional therapies is limited, and the median overall survival (mOS) for advanced-stage gastric cancer is only about 8 months. Emerging as one of breakthroughs for cancer therapy, immunotherapy has become an effective treatment modality after surgery, chemotherapy, radiotherapy, and targeted therapy. In this review, we have summarized the progresses of clinical development of immunotherapies for gastric cancer. Major advances with immune checkpoint inhibitors (ICIs) have started to change the clinical practice for gastric cancer treatment and prognosis. Additionally, combination therapies with other modalities, such as targeted therapies, are expected to push immunotherapies to front-line. In this review, the efficacy of ICIs and targeted therapy alone or combination with existing therapies gastric cancer treatment was described and the predictive value of biomarkers for immunotherapies in gastric cancer treatment is also discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bbcan.2021.188615 | DOI Listing |
Middle East J Dig Dis
October 2024
Department of Laboratory Sciences, School of Allied Medical Sciences, Ahvaze Jundishapur University of Medical Sciences, Ahvaz, Iran.
Background: is a gram-negative pathogen. The infection caused by this pathogen may result in gastritis and can increase the risk of gastric cancer. This study investigated the relationship between infection as the main risk factor for gastritis and changes in serum inflammatory cytokine levels.
View Article and Find Full Text PDFMiddle East J Dig Dis
October 2024
Gastroenterology and Hepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Granular cell tumors (GCTs) of the gastrointestinal tract are rare neoplasms often detected incidentally as subepithelial lesions during endoscopic examination. The occurrence of GCTs in the gastric cavity is even rarer. So far, there have been only four reports of multifocal gastric GCTs.
View Article and Find Full Text PDFBiochem Biophys Rep
March 2025
Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Introduction: Gastric cancer (GC) is among the deadliest malignancies globally, characterized by hypoxia-driven pathways that promote cancer progression, including stemness mechanisms facilitating invasion and metastasis. This study aimed to develop a prognostic decision tree using genes implicated in hypoxia and stemness pathways to predict outcomes in GC patients.
Materials And Methods: GC RNA-seq data from The Cancer Genome Atlas (TCGA) were analyzed to compute hypoxia and stemness scores using Gene Set Variation Analysis (GSVA) and the mRNA expression-based stemness index (mRNAsi).
Front Nutr
December 2024
Department of Medical Oncology, Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Introduction: The relationship between physical activity (PA) and nutritional status on the prognosis of cancer survivors remains underexplored. We aimed to investigate the combined effects of PA and Geriatric Nutritional Risk Index (GNRI) on prognostic assessment of survival outcomes in US cancer survivors.
Methods: 2,619 subjects were screened from the National Health and Nutrition Examination Survey (NHANES) database from 1999 to 2018.
Oncol Lett
March 2025
State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing 400016, P.R. China.
High-intensity focused ultrasound thermal ablation (HIFU) is a novel non-invasive technique in the treatment of liver metastases (LIM) that allows focal destruction and is not affected by dose limits. This retrospective study aimed to explore the efficacy of HIFU in improving survival and the safety of the method in newly diagnosed patients with cancer with LIM who received first-line immune checkpoint inhibitor (ICI) therapy. Between January 2018 and December 2023, data from 438 newly diagnosed patients with cancer and LIM who were treated at Mianyang Central Hospital (Mianyang, China) were reviewed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!